Epidemiology of pain among outpatients in methadone maintenance treatment programs

Lara Dhingra, Carmen Masson, David C. Perlman, Randy M. Seewald, Judith Katz, Courtney Mcknight, Peter Homel, Emily Wald, Ashly E. Jordan, Christopher Young, Russell K. Portenoy

Research output: Contribution to journalArticle

Abstract

Background: This analysis explored the prevalence and correlates of pain in patients enrolled in methadone maintenance treatment (MMT). Methods: Patients in two MMT programs starting a hepatitis care coordination randomized controlled trial completed the Brief Pain Inventory Short-Form and other questionnaires. Associations between clinically significant pain (average daily pain. ≥. 5 or mean pain interference. ≥. 5 during the past week) and sociodemographic data, medical status, depressive symptoms, and health-related quality of life, and current substance use were evaluated in multivariate analyses. Results: The 489 patients included 31.8% women; 30.3% Hispanics, 29.4% non-Hispanic Blacks, and 36.0% non-Hispanic Whites; 60.1% had hepatitis C, 10.6% had HIV, and 46.8% had moderate or severe depressive symptomatology. Mean methadone dose was 95.7. mg (SD 48.9) and urine drug screening (UDS) was positive for opiates, cocaine, and amphetamines in 32.9%, 40.1%, and 2.9%, respectively. Overall, 237 (48.5%) reported clinically significant pain. Pain treatments included prescribed opioids (38.8%) and non-opioids (48.9%), and self-management approaches (60.8%), including prayer (33.8%), vitamins (29.5%), and distraction (12.7%). Pain was associated with higher methadone dose, more medical comorbidities, prescribed opioid therapy, and more severe depressive symptomatology; it was not associated with UDS or self-reported substance use. Conclusions: Clinically significant pain was reported by almost half of the patients in MMT programs and was associated with medical and psychological comorbidity. Pain was often treated with opioids and was not associated with measures of drug use. Studies are needed to further clarify these associations and determine their importance for pain treatment strategies.

Original languageEnglish (US)
Pages (from-to)161-165
Number of pages5
JournalDrug and Alcohol Dependence
Volume128
Issue number1-2
DOIs
StatePublished - Feb 1 2013

Fingerprint

Epidemiology
Methadone
Outpatients
Pain
Opioid Analgesics
Opiate Alkaloids
Screening
Pharmaceutical Preparations
Therapeutics
Amphetamines
Preclinical Drug Evaluations
Cocaine
Vitamins
Comorbidity
Health
Urine
Religion
Hepatitis C
Self Care
Hispanic Americans

Keywords

  • Addiction
  • Epidemiology
  • Methadone maintenance
  • Pain
  • Pain management

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Dhingra, L., Masson, C., Perlman, D. C., Seewald, R. M., Katz, J., Mcknight, C., ... Portenoy, R. K. (2013). Epidemiology of pain among outpatients in methadone maintenance treatment programs. Drug and Alcohol Dependence, 128(1-2), 161-165. https://doi.org/10.1016/j.drugalcdep.2012.08.003

Epidemiology of pain among outpatients in methadone maintenance treatment programs. / Dhingra, Lara; Masson, Carmen; Perlman, David C.; Seewald, Randy M.; Katz, Judith; Mcknight, Courtney; Homel, Peter; Wald, Emily; Jordan, Ashly E.; Young, Christopher; Portenoy, Russell K.

In: Drug and Alcohol Dependence, Vol. 128, No. 1-2, 01.02.2013, p. 161-165.

Research output: Contribution to journalArticle

Dhingra, L, Masson, C, Perlman, DC, Seewald, RM, Katz, J, Mcknight, C, Homel, P, Wald, E, Jordan, AE, Young, C & Portenoy, RK 2013, 'Epidemiology of pain among outpatients in methadone maintenance treatment programs', Drug and Alcohol Dependence, vol. 128, no. 1-2, pp. 161-165. https://doi.org/10.1016/j.drugalcdep.2012.08.003
Dhingra, Lara ; Masson, Carmen ; Perlman, David C. ; Seewald, Randy M. ; Katz, Judith ; Mcknight, Courtney ; Homel, Peter ; Wald, Emily ; Jordan, Ashly E. ; Young, Christopher ; Portenoy, Russell K. / Epidemiology of pain among outpatients in methadone maintenance treatment programs. In: Drug and Alcohol Dependence. 2013 ; Vol. 128, No. 1-2. pp. 161-165.
@article{436bc3a0a7e24f82bcff989084ccbe01,
title = "Epidemiology of pain among outpatients in methadone maintenance treatment programs",
abstract = "Background: This analysis explored the prevalence and correlates of pain in patients enrolled in methadone maintenance treatment (MMT). Methods: Patients in two MMT programs starting a hepatitis care coordination randomized controlled trial completed the Brief Pain Inventory Short-Form and other questionnaires. Associations between clinically significant pain (average daily pain. ≥. 5 or mean pain interference. ≥. 5 during the past week) and sociodemographic data, medical status, depressive symptoms, and health-related quality of life, and current substance use were evaluated in multivariate analyses. Results: The 489 patients included 31.8{\%} women; 30.3{\%} Hispanics, 29.4{\%} non-Hispanic Blacks, and 36.0{\%} non-Hispanic Whites; 60.1{\%} had hepatitis C, 10.6{\%} had HIV, and 46.8{\%} had moderate or severe depressive symptomatology. Mean methadone dose was 95.7. mg (SD 48.9) and urine drug screening (UDS) was positive for opiates, cocaine, and amphetamines in 32.9{\%}, 40.1{\%}, and 2.9{\%}, respectively. Overall, 237 (48.5{\%}) reported clinically significant pain. Pain treatments included prescribed opioids (38.8{\%}) and non-opioids (48.9{\%}), and self-management approaches (60.8{\%}), including prayer (33.8{\%}), vitamins (29.5{\%}), and distraction (12.7{\%}). Pain was associated with higher methadone dose, more medical comorbidities, prescribed opioid therapy, and more severe depressive symptomatology; it was not associated with UDS or self-reported substance use. Conclusions: Clinically significant pain was reported by almost half of the patients in MMT programs and was associated with medical and psychological comorbidity. Pain was often treated with opioids and was not associated with measures of drug use. Studies are needed to further clarify these associations and determine their importance for pain treatment strategies.",
keywords = "Addiction, Epidemiology, Methadone maintenance, Pain, Pain management",
author = "Lara Dhingra and Carmen Masson and Perlman, {David C.} and Seewald, {Randy M.} and Judith Katz and Courtney Mcknight and Peter Homel and Emily Wald and Jordan, {Ashly E.} and Christopher Young and Portenoy, {Russell K.}",
year = "2013",
month = "2",
day = "1",
doi = "10.1016/j.drugalcdep.2012.08.003",
language = "English (US)",
volume = "128",
pages = "161--165",
journal = "Drug and Alcohol Dependence",
issn = "0376-8716",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

TY - JOUR

T1 - Epidemiology of pain among outpatients in methadone maintenance treatment programs

AU - Dhingra, Lara

AU - Masson, Carmen

AU - Perlman, David C.

AU - Seewald, Randy M.

AU - Katz, Judith

AU - Mcknight, Courtney

AU - Homel, Peter

AU - Wald, Emily

AU - Jordan, Ashly E.

AU - Young, Christopher

AU - Portenoy, Russell K.

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Background: This analysis explored the prevalence and correlates of pain in patients enrolled in methadone maintenance treatment (MMT). Methods: Patients in two MMT programs starting a hepatitis care coordination randomized controlled trial completed the Brief Pain Inventory Short-Form and other questionnaires. Associations between clinically significant pain (average daily pain. ≥. 5 or mean pain interference. ≥. 5 during the past week) and sociodemographic data, medical status, depressive symptoms, and health-related quality of life, and current substance use were evaluated in multivariate analyses. Results: The 489 patients included 31.8% women; 30.3% Hispanics, 29.4% non-Hispanic Blacks, and 36.0% non-Hispanic Whites; 60.1% had hepatitis C, 10.6% had HIV, and 46.8% had moderate or severe depressive symptomatology. Mean methadone dose was 95.7. mg (SD 48.9) and urine drug screening (UDS) was positive for opiates, cocaine, and amphetamines in 32.9%, 40.1%, and 2.9%, respectively. Overall, 237 (48.5%) reported clinically significant pain. Pain treatments included prescribed opioids (38.8%) and non-opioids (48.9%), and self-management approaches (60.8%), including prayer (33.8%), vitamins (29.5%), and distraction (12.7%). Pain was associated with higher methadone dose, more medical comorbidities, prescribed opioid therapy, and more severe depressive symptomatology; it was not associated with UDS or self-reported substance use. Conclusions: Clinically significant pain was reported by almost half of the patients in MMT programs and was associated with medical and psychological comorbidity. Pain was often treated with opioids and was not associated with measures of drug use. Studies are needed to further clarify these associations and determine their importance for pain treatment strategies.

AB - Background: This analysis explored the prevalence and correlates of pain in patients enrolled in methadone maintenance treatment (MMT). Methods: Patients in two MMT programs starting a hepatitis care coordination randomized controlled trial completed the Brief Pain Inventory Short-Form and other questionnaires. Associations between clinically significant pain (average daily pain. ≥. 5 or mean pain interference. ≥. 5 during the past week) and sociodemographic data, medical status, depressive symptoms, and health-related quality of life, and current substance use were evaluated in multivariate analyses. Results: The 489 patients included 31.8% women; 30.3% Hispanics, 29.4% non-Hispanic Blacks, and 36.0% non-Hispanic Whites; 60.1% had hepatitis C, 10.6% had HIV, and 46.8% had moderate or severe depressive symptomatology. Mean methadone dose was 95.7. mg (SD 48.9) and urine drug screening (UDS) was positive for opiates, cocaine, and amphetamines in 32.9%, 40.1%, and 2.9%, respectively. Overall, 237 (48.5%) reported clinically significant pain. Pain treatments included prescribed opioids (38.8%) and non-opioids (48.9%), and self-management approaches (60.8%), including prayer (33.8%), vitamins (29.5%), and distraction (12.7%). Pain was associated with higher methadone dose, more medical comorbidities, prescribed opioid therapy, and more severe depressive symptomatology; it was not associated with UDS or self-reported substance use. Conclusions: Clinically significant pain was reported by almost half of the patients in MMT programs and was associated with medical and psychological comorbidity. Pain was often treated with opioids and was not associated with measures of drug use. Studies are needed to further clarify these associations and determine their importance for pain treatment strategies.

KW - Addiction

KW - Epidemiology

KW - Methadone maintenance

KW - Pain

KW - Pain management

UR - http://www.scopus.com/inward/record.url?scp=84872417479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872417479&partnerID=8YFLogxK

U2 - 10.1016/j.drugalcdep.2012.08.003

DO - 10.1016/j.drugalcdep.2012.08.003

M3 - Article

C2 - 22951068

AN - SCOPUS:84872417479

VL - 128

SP - 161

EP - 165

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

SN - 0376-8716

IS - 1-2

ER -